The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis

Xie, Fajun; Lu, Hongyang; Zheng, Quan; Qin, Jing; Gao, Yun; Zhang, Yiping; Hu, Xun; Mao, Weimin

doi:10.2147/ott.s91848

Cited by 23 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apoptosis assay. H1975 (1x10 6 ) and H358 (1x10 6 ) cells were treated with lenvatinib (40 ng/ml), TGF-β1 (40 ng/ml), dexamethasone (20 µM) or combined treatment for 12 h at 37˚C. The cells were incubated with PBS and the apoptosis of the suspended cells was analyzed by flow cytometry.…”

Section: Reverse Transcription-quantitative Polymerase Chain Reactionmentioning

confidence: 99%

“…NSCLC, including squamous cell carcinoma, large cell carcinoma and adenocarcinoma, accounts for >80% of all lung cancer cases (3)(4)(5). Although studies have provided therapeutic improvements for NSCLC, the poor survival rate (overall 5-year survival rate, <15%) of patients with NSCLC is primarily attributed to critical clinical problems, including tumor cell diffusion and metastasis (4,6,7). Migration and invasion of NSCLC is the primary cause of the poor survival rate during treatment and recurrence for patients with NSCLC (8,9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Zhang

Cai

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Migration and invasion is one of the most important features in tumor metastasis and development. Non-small cell lung cancer (NSCLC) is one of the most common types of cancer globally, and has been linked to air contamination. Evidence indicates that cysteine-rich angiogenic inducer 61 (CYR61) is associated with the migration and invasion of NSCLC. Overexpression of CYR61 protein promotes the migration and the transition of tumor-derived vascular endothelial cells in NSCLC. However, the association between CYR61 and NSCLC remains poorly understood. Lenvatinib is an oral multi-target drug that targets various receptors upon tumor angiogenesis. Dexamethasone is widely approved for combination therapy in patients with NSCLC. In the current study, the expression and function of CYR61 in NSCLC was analyzed during the progression of NSCLC. Inhibitory effects on migration and invasion induced by lenvatinib and dexamethasone were determined by migratory and invasion assays. Migratory pathways of extracellular signal-regulated kinases (ERK) and protein kinase B (AKT) were also investigated by targeting vascular endothelial growth factor (VEGF) and CYR61 via synergistic treatment with transforming growth factor-β1 (TGF-β1) and dexamethasone. Therapeutic outcomes of combined treatment with lenvatinib and dexamethasone were assessed in NSCLC-bearing mice. The results of the present study indicate that cooperative treatment of lenvatinib and dexamethasone significantly inhibited TGF-β1-induced cell migration and suppressed tumor growth (P<0.01). Notably, the results demonstrated that dexamethasone eradicated the promotion effects of TGF-β1 on the AKT/epithelial-mesenchymal transition process and lenvatinib extinguished tumor cell metastasis by targeting VEGF. The results of the current study also demonstrate that dexamethasone suppressed the expression of CAG-I and enhanced expression of matrix metalloproteinase-1. Synergistic treatment for NSCLC was demonstrated to be efficacious. In conclusion, dexamethasone inhibited AKT/ERK phosphorylation and lenvatinib antagonism bound VEGF leading to the limitation of migration and invasion of cancer cells in NSCLC.

show abstract

Section: Reverse Transcription-quantitative Polymerase Chain Reactionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Zhang

Cai

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…It is generally considered that tumorigenesis is a complex process with a wide spectrum of genetic alterations [6]. These genes typically exhibit aberrant expression patterns and have clinical significance in cancer diagnosis and prognosis [7]. Currently, some molecules have been recognized as diagnostic and prognostic biomarkers in oligodendroglial tumor.…”

Section: Introductionmentioning

confidence: 99%

Screening and Authentication of Key Genes and Prognostic Value Analysis in Oligodendroglial Tumors

Bao

Peng

2020

Preprint

View full text Add to dashboard Cite

Background: Emerging evidence indicates that various functional genes with altered expression are involved in the human tumor progression. This study is aimed at identifying novel key genes that may be used for oligodendroglial tumor diagnosis, prognosis, and targeted therapy. Methods: This study included three expression proﬁles (GSE15824, GSE29796 and GSE108474) obtained from the Gene Expression Omnibus (GEO). GEO2R was used to analyze the diﬀerentially expressed genes (DEGs) between normal samples and oligodendroglial tumor, including oligodendroglioma and anaplastic oligodendroglioma. The functional and pathway enrichment analysis was performed by the Database for Annotation, Visualization and Integrated Discovery. A protein-protein interaction (PPI) network of the identiﬁed DEGs was constructed using the Search Tool for the Retrieval of Interacting Gene, and hub genes were identiﬁed. ONCOMINE and The Cancer Genome Atlas (TCGA) databases were used to verify the expression of the hub genes in oligodendroglial tumor tissues and the hub genes on the overall survival of oligodendroglial tumor patients. Results: A total of 128 DEGs were identiﬁed from the three expression proﬁles. These DEGs were enriched with functional processes and pathways related to oligodendroglial tumor pathogenesis. From the PPI network, five hub genes were identiﬁed. The expression of the five hub genes was all upregulated in oligodendroglial tumor tissues compared with the control tissues. Kaplan-Meier survival curves indicated that high expression of cullin 3 (CUL3), cop9 signalosome subunit 8 (COPS8), cullin associated and neddylation dissociated 1 (CAND1), F-box protein 22 (FBXO22), and leucine rich repeat containing 41 (LRRC41) predicted poor overall survival in oligodendroglial tumor patients (all log-rank P < 0.01). Conclusions: These results revealed that the DEGs may serve as candidate key genes during oligodendroglial tumor pathogenesis. The five hub genes, including CUL3, COPS8, CAND1, FBXO22, and LRRC41, may serve as promising prognostic biomarkers in oligodendroglial tumor.

show abstract

“…A previous pathological study has suggested that NSCLC accounts for ~80% of all lung cancer cases and classified adenocarcinoma, large cell carcinoma and squamous cell carcinoma as common types of NSCLC (4). A number of therapeutic strategies, such as immunotherapy, gene therapy, radiotherapy and chemotherapy, have been widely applied in clinical settings for the treatment of NSCLC (5-7); however, poor survival rates of patients with NSCLC have continued (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non‑small cell lung cancer patients

Zhang

Chu

2018

Exp Ther Med

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the most prevalent human cancers, which is known for local growth, easily migration, long-distance invasion and reoccurrence. Targeted ultrasound (US) contrast combined with ultrasound for lung cancer diagnosis has been applied in the clinic. In the present study, a novel targeted ultrasound contrast agent containing chistosan/FeO-parceled bispecific antibody (TcBab) targeting carcino-embryonic antigen, vascular endothelial growth factor receptor was introduced, and the diagnostic accuracy and sensitivity was investigated in patients with NSCLC. A total of 384 patients with suspected NSCLC were recruited to investigate the accuracy of TcBab-ultrasound (TcBab-US) and ultrasound. Results demonstrated that TcBab-US improved sensitivity and may provide a novel protocol for diagnosing tumors in patients with suspected NSCLC at an early stage. Data analysis demonstrated that TcBab-US diagnosed 154 suspected patients with NSCLC, whereas ultrasound only diagnosed 84 suspected patients with NSCLC out of a total of 384 patients with suspected NSCLC (P<0.01). A dosage experiment revealed that the optimal dose of TcBab was 5 mg/kg for NSCLC patients. Pharmacodynamics analysis showed that TcBab may be metabolized within 16 h in serum of patients. Notably, early diagnosis determined by TcBab-US contributed to improvement of survival for NSCLC patients as determined by a comparison of the survival rate with the survival rate of patients who did not receive TcBab (P<0.05). In conclusion, these investigations suggested that TcBab improves the accuracy and diagnostic confidence of ultrasonic for the diagnosis of early-stage NSCLC, and may have potential application value in the clinic.

show abstract

The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis

Cited by 23 publications

References 35 publications

Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways

Screening and Authentication of Key Genes and Prognostic Value Analysis in Oligodendroglial Tumors

Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non‑small cell lung cancer patients

Contact Info

Product

Resources

About